贝伐珠单抗联合白蛋白结合型紫杉醇以及奈达铂治疗复发宫颈癌患者的效果分析  

Effect analysis of bevacizumab combined with albumin-bound paclitaxel and nedaplatin in patients with recurrent cervical cancer

作　　者：施彩 Shi Cai(Department of Oncology,Siping Central People's Hospital,Siping 136000,China)

机构地区：[1]四平市中心人民医院肿瘤科,吉林四平136000

出　　处：《实用妇科内分泌电子杂志》2024年第8期50-52,共3页Electronic Journal of Practical Gynecological Endocrinology

摘　　要：目的探析贝伐珠单抗联合白蛋白结合型紫杉醇、奈达铂治疗复发宫颈癌患者的临床效果。方法选取40例复发宫颈癌患者,根据随机数字表法分为对照组与研究组,各20例。对照组接受贝伐珠单抗、紫杉醇、顺铂联合化疗方案,研究组接受贝伐珠单抗、白蛋白结合型紫杉醇、奈达铂联合化疗方案。比较两组临床疗效、治疗前后肿瘤标志物指标、不良反应发生情况。结果研究组总有效率为80.00%,高于对照组的50.00%(P<0.05)。治疗后研究组的癌胚抗原(CEA)、鳞状细胞癌抗原(SCC)指标低于对照组(P<0.05)。研究组不良反应发生率10.00%低于对照组的40.00%(P<0.05)。结论采取贝伐珠单抗联合白蛋白结合型紫杉醇以及奈达铂方案治疗复发宫颈癌患者,对于病情改善具有积极影响,有效降低肿瘤标志物指标,用药安全性较高,具有较高的临床应用价值。Objective To explore the clinical effect of bevacizumab combined with albumin-bound paclitaxel and nedaplatin in the treatment of patients with recurrent cervical cancer.Methods 40 patients with recurrent cervical cancer were selected as the study objects,and were divided into control group and study group,with 20 patients in each group.The control group received combination chemotherapy with bevacizumab,paclitaxel and cisplatin,while the study group received combination chemotherapy with bevacizumab,albumin-bound paclitaxel and nedaplatin.The clinical effcacy,tumor markers before and after treatment and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the study group was 80.00%,which was higher than that of the control group 50.00%(P<0.05).After treatment,the CEA and SCC indexes of the study group were lower than those of the control group(P<0.05).The incidence of adverse reactions in the study group(10.00%)was lower than that in the control group(40.00%)(P<0.05).Conclusion The combination of bevacizumab with albumin-bound paclitaxel and nedaplatin in the treatment of patients with recurrent cervical cancer has a positive effect on the condition,effectively improves the tumor markers,and has high drug safety and clinical application value.

关 键 词：贝伐珠单抗 白蛋白结合型紫杉醇 奈达铂 复发 宫颈癌 

分 类 号：R737.33[医药卫生—肿瘤]